Literature DB >> 20557670

The expression of LMO2 protein in acute B-cell and myeloid leukemia.

Umit Cobanoglu1, Mehmet Sonmez, Hasan Mucahit Ozbas, Nergis Erkut, Gamze Can.   

Abstract

LIM domain only-2 (LMO2) is an important regulator of hematopoietic stem cell development. LMO2 is also expressed in blast cells of different types of acute leukemia. Here, we analyzed the LMO2 protein expression in acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL) and examined whether the LMO2 protein expression can predict outcomes of patients with acute leukemia. Patients with acute B-ALL (22 cases) and AML (57 cases) were examined using immunohistochemistry for LMO2 on paraffin-embedded bone marrow biopsies. We report that LMO2 protein is expressed in a significant proportion of B-ALL and AML and the staining of LMO2 protein does not predict survival in acute leukemia.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20557670     DOI： 10.1179/102453309X12583347113618

Source DB:  PubMed          Journal:  Hematology        ISSN： 1024-5332            Impact factor:   2.269


  6 in total

1.  LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.

Authors:  Raquel Malumbres; Vicente Fresquet; Jose Roman-Gomez; Miriam Bobadilla; Eloy F Robles; Giovanna G Altobelli; M José Calasanz; Erlend B Smeland; Maria Angela Aznar; Xabier Agirre; Vanesa Martin-Palanco; Felipe Prosper; Izidore S Lossos; Jose A Martinez-Climent
Journal:  Haematologica       Date:  2011-04-01       Impact factor: 9.941

2.  High expression of LMO2 predicts a favorable outcome in adult patients with BCR/ABL negative B-cell acute lymphoblastic leukemia.

Authors:  Rabab M Aly; Mona M Taalab; Eman M Abdsalam; Omar H Elyamany; Omar E Hasan
Journal:  Oncol Lett       Date:  2016-01-19       Impact factor: 2.967

3.  The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.

Authors:  V Novotny-Diermayr; S Hart; K C Goh; A Cheong; L-C Ong; H Hentze; M K Pasha; R Jayaraman; K Ethirajulu; J M Wood
Journal:  Blood Cancer J       Date:  2012-05-04       Impact factor: 11.037

4.  Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.

Authors:  Lynn M Heltemes-Harris; Mark J L Willette; Laura B Ramsey; Yi Hua Qiu; E Shannon Neeley; Nianxiang Zhang; Deborah A Thomas; Thearith Koeuth; Emily C Baechler; Steven M Kornblau; Michael A Farrar
Journal:  J Exp Med       Date:  2011-05-23       Impact factor: 14.307

5.  Genetic barcode sequencing for screening altered population dynamics of hematopoietic stem cells transduced with lentivirus.

Authors:  Daniela B Zanatta; Maristela Tsujita; Primavera Borelli; Rodrigo B Aguiar; Daniel G Ferrari; Bryan E Strauss
Journal:  Mol Ther Methods Clin Dev       Date:  2014-11-19       Impact factor: 6.698

6.  The LMO2 -25 Region Harbours GATA2-Dependent Myeloid Enhancer and RUNX-Dependent T-Lymphoid Repressor Activity.

Authors:  Nicolas Bonadies; Berthold Göttgens; Fernando J Calero-Nieto
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.